Mitochondrial DNA Haplogroup Analysis Reveals no Association between the Common Genetic Lineages and Prostate Cancer in the Korean Population

Wook Kim1*, Tag-Keun Yoo2, Dong-Jik Shin3, Hyun-Wook Rho1, Han-Jun Jin1, Eun-Tak Kim4, Yoon-Sun Bae3

1 Department of Biological Sciences, Dankook University, Cheonan, Korea, 2 Department of Urology, Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea, 3 Cardiovascular Genome Center, Yonsei University College of Medicine, Seoul, Korea, 4 Department of Urology, Eulji University School of Medicine, Daejeon, Korea

Abstract

Mitochondrial DNA (mtDNA) variation has recently been suggested to have an association with various cancers, including prostate cancer risk, in human populations. Since mtDNA is haploid and lacks recombination, specific mutations in the mtDNA genome associated with human diseases arise and remain in particular genetic backgrounds referred to as haplogroups. To assess the possible contribution of mtDNA haplogroup-specific mutations to the occurrence of prostate cancer, we have therefore performed a population-based study of a prostate cancer cases and corresponding controls from the Korean population. No statistically significant difference in the distribution of mtDNA haplogroup frequencies was observed between the case and control groups of Koreans. Thus, our data imply that specific mtDNA mutations/lineages did not appear to have a significant effect on a predisposition to prostate cancer in the Korean population, although larger sample sizes are necessary to validate our results.

Introduction

Prostate cancer is one of the most common cancers and the second leading cause of cancer mortality in Caucasian men, but its incidence varies considerably between human populations [1]. Based on a recent survey, an approximately 1.6-fold greater incidence of prostate cancer was diagnosed and a 2.4-fold greater mortality reported in African-American men compared to European-American men [2]. In addition, Asian populations have shown a general trend of rising incidence of the cancer after adopting westernized lifestyles, although the incidence is still lower in Asia than Western countries [3,4]. It appears that multiple variables including ethnic origins, environmental, and genetic factors are likely linked to prostate cancer [5–8].

Mitochondria have been implicated in malignancy and cancer biology, explained by their essential role in the generation of ATP and for regulating apoptosis [9,10]. Recent studies suggest that mitochondrial DNA (mtDNA) mutations may play an important role in prostate carcinogenesis. For instance, a transmitsochondrial cybrid experiment demonstrated that the resulting mutant cybrids appeared to generate tumors that were seven times larger than the wild-type cybrids, whereas the wild-type cybrids barely grew in the mice [7]. Jessie et al. [11] found that the average number of mtDNA deletions in the malignant prostate of patients increased with age. In addition, somatic mtDNA mutations that occur well before changes in tissue histopathology indicative of prostate cancer are highly informative about the oncogenesis of the disease [12].

Since mtDNA is haploid and lacks recombination, specific mutations in the mtDNA genome leading to human diseases arise in particular genetic backgrounds referred to as haplogroups [13]. Human populations usually carry several mtDNA haplogroups defined by unique sets of mtDNA polymorphisms, reflecting mutations accumulated by a discrete maternal lineage [14,15], but the sets and their frequencies differ between populations. Thus, haplogroup association studies have been used to assess the role of mtDNA variants in various complex diseases. Recently, Booker et al. [8] noted that the inheritance of mtDNA haplogroup U was associated with an approximately 2-fold increased risk of prostate cancer and 2.5-fold increased risk of renal cancer in North American individuals with European ancestry. Such a finding needs to be investigated in an independent population to determine whether a causal role of mtDNA haplogroups in the cancer can also be detected elsewhere, for example in the different maternal lineages in east Asia.

To assess the possible contribution of mtDNA haplogroup-specific mutations to the occurrence of prostate cancer, we have therefore investigated the association between common mtDNA lineages and a predisposition to the cancer in the Korean population by examining 139 prostate cancer cases and 122 corresponding controls.
**Methods**

**Patients and controls**

We analyzed a total of 139 Korean prostate cancer patients, who were recruited for the study from the urology department of the Eulji University School of Medicine in Seoul and Daejeon, Korea. The DNA samples included subsets of the samples examined by Kim et al. [16]. Histological classification of prostate cancer was determined according to the World Health Organization (WHO) recommendations and the Gleason pattern (Table 1). Prostate cancer tissue specimens from all of the patients were collected from frozen samples. In addition, a total of 122 Korean men who had been diagnosed as free of prostate cancer by the Eulji University hospital in Seoul and Daejeon, Korea were recruited as normal controls. These subjects were selected at random (and therefore likely to be unrelated) from the same geographical area as the cases. This study was approved by the Ethics Committee and institutional review boards of Eulji Medical Center of the Eulji University School of Medicine in Seoul, and separate written informed consent was obtained for screening and for enrollment from all participants.

**DNA extraction and genotyping**

Genomic DNAs for patients and controls were extracted from peripheral blood leukocytes using standard protocol [17]. Screening for mtDNA haplogroups D, D4a, D4b, G, M7, M7a, M7b, M8a, M, N, N9, Y, A, B, and F in Koreans (Table 2) was performed using the multiplex amplified product length polymorphism (APLP) method [18]. Each PCR reaction was performed in a total volume of 20 μl containing 25 ng of genomic DNA, 0.2 mM dNTPs, 1.5 mM MgCl2, 1× PCR buffer (Applied Biosystems, Foster City, CA, USA), 1.0 U ampliTaq Gold™ DNA polymerase (Applied Biosystems, Foster City, CA, USA) and appropriate concentration of primers. Primers and concentrations were described in Umemoto et al. [18]. The PCR amplification was carried out using a GeneAmp® PCR system 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) under the conditions: 95°C for 15 min, 32 cycles of 94°C for 10 sec, 52°C for 10 sec, 72°C 5 sec, and a final extension at 72°C for 5 min. The band patterns of the alleles were evaluated on 10% native PAGE gels and visualized by silver staining. Haplogroups D5, G2, C, B5 and F1 (Table 2) were determined by PCR-RFLP method [19]. The resulting restriction fragments were resolved by electrophoresis in 1.5% QA-Agarose™ agarose (Q-BioGene, OH, USA) gels, visualized by ethidium bromide staining. The nomenclature of the mtDNA haplogroups in this study.

**Table 1. Clinicopathological characteristics of Korean prostate cancer patients and control groups surveyed here.**

| Characteristic | Prostate Cancer Patient (n = 139) | Control (n = 122) |
|---------------|----------------------------------|------------------|
| Age (year)    | ≤55                              | 39 (31.97%)      |
|               | 56–60                            | 20 (16.39%)      |
|               | 61–65                            | 33 (27.05%)      |
|               | >65                              | 30 (24.59%)      |
| PSA (mg/ml)   | ≤4.0                             | 113 (92.62%)     |
|               | 4.1–10.0                         | 3 (2.46%)        |
|               | 10.1–20.0                        | 3 (2.46%)        |
|               | >20.0                            | -                |
|               | Not available                     | 3 (2.46%)        |
| Gleason score | 2–6                              | -                |
|               | 7                                | -                |
|               | 8–10                             | -                |
|               | Not available                     | 1 (0.72%)        |

*Mean age: ±SD.

**Table 2. Polymorphic multiplex APLP and restriction variants determining mtDNA haplogroups in this study.**

| Haplogroup | Key multiplex APLP and restriction variants |
|------------|--------------------------------------------|
| M*         | 10400T                                     |
| D4         | 3010A 5178A 10400T                          |
| D4a        | 3010A 5178A 10400T 14979C                   |
| D4b        | 3010A 5178A 8020A 10400T                    |
| D5         | 5178A -10394Δdel/-10397Δdel/10400T           |
| G2         | 4833G 10400T                               |
| M7*        | 6455T 10400T                               |
| M7a        | 4386C 6455T 10400T                         |
| M7b        | 6455T 10400T 12811C                         |
| M8*        | 10400T 15487T                              |
| M8a        | 8684T 10400T 15487T                         |
| N1         | 10398A/10873T                              |
| N9*        | 5417A 10398A/10873T                         |
| Y          | 5417A 10398A/10873T 14178C                  |
| A          | 1736G 10398A/10873T                         |
| B*         | 9-bp deletion 10398A/10873T                |
| BS         | 9-bp deletion 10398A/10873T                |
| F1         | 3970T 10398A/10873T                         |

*Sites are numbered from the first nucleotide of the recognition sequence. A plus sign (+) indicates the presence of a restriction site, and a minus sign (−) indicates the absence of restriction site.

**Data analyses**

Mitochondrial DNA haplogroup frequencies were calculated by counting from the observed phenotypes. To test for significant population differentiation between all pairs of samples for the prostate cases and the control groups, we used an Exact Test implemented in the Arlequin package version 2.0 [22]. The significance level of the test was applied with a probability of <0.05 as cutoff point. In addition, a test of proportion and odds ratios (OR) with 95% confidence intervals (CI), and a Fisher’s Exact Test on a 2×2 table were calculated using the statistical software program (http://www.quantitativeskills.com/sisa/).

**Results and Discussion**

We analyzed 22 mtDNA haplogroups using APLP and PCR-RFLP methods in the cancer and control samples, most of which are the common set of haplogroups in east Asia. The haplogroup
based phylogenetic analysis used here enhances mtDNA database quality, thus minimizing noise that would hinder the interpretation of the variation in our samples [23]. Frequency distributions of the prevalence of mtDNA haplogroups and subhaplogroups in Koreans are listed in Figure 1. The Korean population surveyed here is characterized by a high frequency of haplogroup D4 lineages (and its sublineages) in both groups of prostate cancer patients (28.8%) and normal controls (27.9%) (Figure 1). In total, thus, mtDNA haplogroups D and their subhaplogroups (D4a, D4b, D4, and D5) were found to be the most prevalent maternal lineages in both samples of prostate cancer patients (36.0%) and normal controls (36.9%), and are widespread in northeast Asia. In addition, southeast Asian-prevalent mtDNA lineages of (sub)haplogroups B, M7, and F are also found at moderate frequencies in the population. This result is consistent with previous mtDNA and Y-chromosomal DNA surveys, showing that the Koreans possess lineages from both the southern and northern haplogroup complexes of east Asia [20,24].

Haplogroup U, reported by Booker et al. [8] to be over-represented in prostate cancer patients in North American individuals, was absent from our sample, which made it impossible to assess the correlation between this lineage and cancer cases. Based on our result, there were no statistically significant differences in the distribution of mtDNA haplogroup frequencies between all pairs of samples for the case and control groups (Figure 1). In addition, each haplogroup was first tested separately and then phylogenetically-combined haplogroups were tested using OR and their 95% CI, and a Fisher’s exact test (Table 3). We found no association between the cancer and the control groups for each haplogroup. When comparing the distribution of phylogenetically-combined haplogroups in patients to that in the control group, there were again no significant differences between cancer groups and the control distribution for haplogroups D, G, M7, M8, N9, B, and F (Table 3). Thus, our data imply that specific mtDNA mutations/lineages did not appear to have a significant effect on a predisposition to prostate cancer in the Korean population. However, the sample size of this survey may not provide adequate power to detect associations with the large number of haplogroups present in the sample (Figure 1). Thus, further studies with larger sample sizes are necessary to validate our results, because even association with fairly common haplogroups and large effects may be missed with the limited sample sizes.

Recently, Kim et al. [16] also found no association between Y chromosome haplogroups and the relative risk of prostate cancer, which contrasts with previous findings in the Japanese-American population [25]. Nuclear gene mutations have also been linked to mitochondrial diseases because most proteins involved in mtDNA maintenance are nuclear-encoded [15]. Thus, further works on nuclear gene disorders that contribute to the onset of the mitochondrial diseases need to be investigated for better understanding of the pathogenesis of the disease.

Age and family history are important risk factors for prostate cancer, together with geographical origin [26]. We cannot rule out the possibility of the effect of age difference between the case and control samples, since it is not clear whether some controls may subsequently go on to develop prostate cancer. In fact, it should be noted that the mean age of controls (59.6±10.8) is less than that of cancer patients (70.6±8.3) (Table 1). Nevertheless, this effect seems likely to be small. Recent surveys from Asia (e.g., Japan, Singapore and Korea) have shown a general trend of a rising incidence of prostate cancer [3]. The changing demography of prostate cancer in Asia may better be explained by environmental factors. This possibility is supported by the observation that many Asian countries may be losing their protective dietary habits and acquiring high-risk ones by adopting westernized lifestyles [4,16]. It leads us to conclude that multiple variables including ethnic background, environmental, and genetic factors are likely linked to prostate cancer.
Thus, further surveys on analyses of this association using additional genetic markers and larger diverse samples could help to evaluate the joint actions of genetic background and environmental factors for the fuller understanding of the etiology of prostate cancer.

Acknowledgments

We would like to thank all DNA donors for making this study possible. Special thanks go to all the urologists and pathologists in Eulji Medical Center of the Eulji University hospital. Comments and discussion on this manuscript by Chris Tyler-Smith (The Wellcome Trust) were also greatly appreciated.

Author Contributions

Conceived and designed the experiments: WK TY DS. Performed the experiments: DS HJ EK YB HR. Analyzed the data: WK HJ. Contributed reagents/materials/analysis tools: WK TY. Wrote the paper: WK.

References

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. Ca Cancer J Clin 51: 15–36.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer Statistics. Ca Cancer J Clin 55: 10–30.
3. Hsing AW, Deng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, et al. (2000) Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 9: 1335–1341.
4. Sim HG, Cheng CW (2005) Changing demography of prostate cancer in Asia. Eur J Cancer 41: 834–843.
5. Brothman AR, Maxwell TM, Cui J, Deubler DA, Zhu XL (1999) Chromosomal clues to the development of prostate tumors. Prostate 38: 303–312.
6. Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA (2004) Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 93: 1139–1150.
7. Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, et al. (2005) MitDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA 102: 719–724.
8. Booker LM, Habermacher GM, Jessie BC, Sun QC, Baumann AK, et al. (2006) North American white mitochondrial haplogroups in prostate and renal cancer. J Urol 175: 468–473.
9. van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, et al. (2003) Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 72: 804–811.
10. Wallace DC (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 39: 359–407.
11. Jessie BC, Sun CQ, Irons HR, Marshall FF, Wallace DC, et al. (2001) Accumulation of mitochondrial DNA deletions in the malignant prostate of patients of different ages. Exp Gerontol 36: 169–174.
12. Parr RL, Dakubo GD, Cranford KA, Maki J, Reguly B, et al. (2006) Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 8: 312–319.
13. Pakendorf B, Stoneking M (2005) Mitochondrial DNA and human evolution. Annu Rev Genomics Hum Genet 6: 165–183.
14. Torroni A, Huoponen K, Francalacci P, Petrozzi M, Morelli I, et al. (1996) Classification of European mtDNAs from an analysis of three European populations. Genetica 100: 1835–1850.
15. Taylor RW, Turnbull DM (2005) Mitochondrial DNA mutations in human disease. Nat Rev Genet 6: 389–402.
16. Kim W, Yoo TK, Kim SJ, Shin DJ, Tyler-Smith C, et al. (2007) Lack of association between Y-chromosomal haplogroups and prostate cancer in the Korean population. PLoS ONE 2: e172.
17. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning: A laboratory manual, 2nd edn. New York: Cold Spring Harbor Laboratory Press.
18. Umetsu K, Tanaka M, Yuasa I, Adachi N, Miyoshi A, et al. (2005) Multiplex amplified product-length polymorphism analysis of 36 mitochondrial single-nucleotide polymorphisms for haplogrouping of East Asian populations. Electrophoresis 26: 91–98.
19. Derenko MV, Lunikina AV, Miharchuk BA, Zakharov IA, Tsetsiev T, et al. (2004) Restriction polymorphism of mitochondrial DNA in Koreans and Mongolians. Genetika 40: 1562–1570.
20. Kivisild T, Toik KV, Park J, Wang Y, Papiha SS, et al. (2002) The emerging limbs and twigs of the East Asian mtDNA tree. Mol Biol Evol 19: 1737–1751.
21. Kong QP, Bandelt HJ, Sun C, Yao YG, Salas A, et al. (2006) Updating the East Asian mtDNA phylogeny: a prerequisite for the identification of pathogenic mutations. Hum Mol Genet 15: 2076–2086.
22. Schneider S, Roessli D, Excoffier L (2000) Arlequin: a software for population genetics data analysis, 2.000 edn, Genetics and Biometry Lab, Dept of Anthropology, University of Geneva.
23. Salas A, Yao YG, Macaulay V, Vega A, Carreco A, et al. (2005) A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med 2: e296.
24. Jin HJ, Kwak KD, Hammer MF, Nakahori Y, Shinka T, et al. (2003) Y-chromosomal DNA haplogroups and their implications for the dual origins of the Koreans. Hum Genet 114: 27–35.
25. Paracchini S, Pearce CL, Kolonek LN, Altshuler D, Henderson BE, et al. (2003) A Y chromosomal influence on prostate cancer risk: the multi-ethnic cohort study. J Med Genet 40: 815–819.
26. Bostwick DG, Burke HB, Djakiew D, Ealing S, Ho SM, et al. (2004) Human prostate cancer risk factors. Cancer 101: 2371–2490.